NasdaqGM:MNKDBiotechs
MannKind (MNKD) Stock Faces Margin Strain Despite Stronger Product Sales
MannKind stock came into this earnings print already under pressure, and the latest numbers knocked it another 5% lower to US$3.89. The move appears driven less by revenue and more by the profit squeeze. Q2 revenue reached US$109.4m, while the company reported a GAAP net loss of US$19.0m, as launch spending and higher operating costs weighed on results.
For a biotech trying to build around Afrezza and Furoscix, this quarter tested investor patience. The core question now is whether this level...